SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
6-K	Aug 28, 2026	Aug 28, 2026	View filing
6-K	Aug 27, 2026	Aug 27, 2026	View filing
6-K	Aug 20, 2026	Aug 20, 2026	View filing
6-K	Aug 4, 2026	Aug 4, 2026	View filing
6-K	Aug 4, 2026	Aug 4, 2026	View filing
6-K	Aug 3, 2026	Aug 3, 2026	View filing
20-F/A	Jul 30, 2026	Jul 30, 2026	View filing
6-K	Jul 29, 2026	Jul 29, 2026	View filing
3	Jun 26, 2026	Jun 26, 2026	View filing
3	Jun 26, 2026	Jun 26, 2026	View filing
6-K	Jun 8, 2026	Jun 8, 2026	View filing
6-K	Jun 1, 2026	Jun 1, 2026	View filing
6-K	May 22, 2026	May 22, 2026	View filing
6-K	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
6-K	May 7, 2026	May 7, 2026	View filing
6-K	May 5, 2026	May 5, 2026	View filing
6-K	May 5, 2026	May 5, 2026	View filing
4	Apr 23, 2026	Apr 23, 2026	View filing
3/A	Apr 13, 2026	Apr 13, 2026	View filing
6-K	Apr 13, 2026	Apr 13, 2026	View filing
6-K	Apr 2, 2026	Apr 2, 2026	View filing
20-F/A	Apr 1, 2026	Apr 1, 2026	View filing
3	Mar 25, 2026	Mar 25, 2026	View filing

About BioNTech SE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Mainz, RP

7,807 employees

www.biontech.com/de/de/home.html

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ugur Sahin

View full financials